Clinical Trial

Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability, recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of IBR733 cell injection in relapsed/refractory acute myeloid leukemia (AML).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-30.
Status change: Not Yet Recruiting → Recruiting 2026-07-01
Trial Details
NCT Number NCT06234904
Lead Sponsor Imbioray (Hangzhou) Biomedicine Co., Ltd.
Collaborators: The First Affiliated Hospital of Soochow University
Conditions Acute Myeloid Leukemia
Enrollment 18 participants
Start Date 2024-03-26
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-02